Roche's Kadcyla® (ado-trastuzumab emtansine, formerly T-DM1)

In the US, Kadcyla is marketed by Genentech, a member of the Roche Group. US healthcare providers and patients should refer to Genentech’s Kadcyla website for information on this product.

Kadcyla consists of our DM1 cell-killing agent attached to Roche’s HER2-targeting antibody, trastuzumab, using our SMCC linker (“emtansine” is DM1 attached using SMCC).

Roche, including Genentech, has been implementing an impressive Kadcyla program. The results from the first Kadcyla Phase III trial, EMILIA, were featured in a plenary session at ASCO in 2012, published in the prestigious New England Journal of Medicine, and formed the basis for the first approvals of Kadcyla in the US, Europe, Japan, and other countries around the world.

Other Phase III trials are underway with Kadcyla, assessing it for additional uses. Information on the status of these trials is typically included in Roche quarterly updates and in ImmunoGen quarterly releases.

Kadcyla® is a registered trademark of Genentech, Inc., a member of the Roche Group.

Last updated: March 30, 2015

You are now leaving this website. If you would like to continue, click Continue.